Merck & Company News - July 2026
🟢 Merck is trading 3.1% up today after FDA approval of oral cholesterol drug Lipfendra
Merck is trading 3.1% up at $131.54 after winning FDA approval for Lipfendra, the first once-daily oral PCSK9 inhibitor for lowering LDL cholesterol in...
Merck Wins FDA Approval for Lipfendra, First Oral Cholesterol-Lowering Pill
The U.S. Food and Drug Administration approved Merck’s Lipfendra (enlicitide) for the treatment of hypercholesterolemia. This once-daily pill represents the...
Merck Keytruda Beats Chemotherapy, Offering New Option for Endometrial Cancer
Merck’s Phase 3 KEYNOTE-C93 trial met its primary endpoint for the treatment of endometrial cancer. Keytruda monotherapy significantly improved...